Extended vs. No Pelvic Lymph Node Dissection During Radical Prostatectomy. DISSECTION 2.0.
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18+
SponsorUniversity Hospital, Basel, Switzerland
About this trial
The aim of the DISSECTION 2.0 study is to determine whether extended pelvic lymph node dissection (ePLND) provides a therapeutic benefit for high-risk prostate cancer patients by improving cancer staging and potentially removing micrometastatic disease, ultimately improving their outcomes.
Eligibility criteria
Qualifiers
Age ≥ 18 years and life expectancy >15 years
Any biopsy-proven WHO/ISUP grade groups III-V PCa
Any biopsy-proven WHO/ISUP grade group III-V PCa or
ISUP grade group II and PSA > 20 ng/ml
Disqualifiers
ISUP grade group I PCa and cT1 or cT2 (MRI)
cT4 (MRI) PCa
PSMA-PET: positive staging for local and distant metastasis
Any prior neoadjuvant, local or systemic treatment for PCa
Trial design
Treatments tested in this trial
- Extended Pelvic Lymph Node Dissection
Treatment groups
400 Participants
are divided into 2 treatment groupsLocations
15Cantonal Hospital Aarau Aarau Switzerland
University Hospital Basel4031, Basel Switzerland
Inselspital Bern Switzerland
Lindenhof Hospital Bern Switzerland
Sponsors and collaborators
University Hospital, Basel, Switzerland
Lead sponsor
Source ClinicalTrials.gov